Education
About Us
Working with TipRanks
Follow Us
China Resources Pharmaceutical Group Ltd. (HK:3320)
:3320
RESEARCH TOOLSreports
3320 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$4.61 - HK$7.11
Previous CloseN/A
Volume6.08M
Average Volume (3M)8.67M
Market Cap
€33.99B
Enterprise ValueHK$89.12B
Total Cash (Recent Filing)€17.48B
Total Debt (Recent Filing)HK$73.43B
Price to Earnings (P/E)9.4
Beta0.91
Next Earnings
Aug 21, 2025EPS Estimate
0.42Last Dividend Ex-Date
May 28, 2025Dividend Yield4.77%
Share Statistics
EPS (TTM)0.12
Shares Outstanding6,282,510,300
10 Day Avg. Volume8,089,365
30 Day Avg. Volume8,666,476
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-927.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
China Resources Pharmaceutical Group Ltd. News
PremiumCompany Announcements
China Resources Pharmaceutical Group Appoints New Non-Executive Director
PremiumCompany Announcements
China Resources Pharmaceutical Completes Third Tranche Bond Issuance
PremiumCompany Announcements
China Resources Pharmaceutical Announces AGM Results and Board Changes
PremiumCompany Announcements
CR Sanjiu Reports Q1 2025 Financial Results with Strong Cash Flow
PremiumCompany Announcements
Tasly Pharmaceuticals Reports Q1 2025 Financial ResultsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.53%
Mutual Funds
― Other Institutional Investors
95.74% Public Companies and
Individual Investors
3320 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was HK$4.61 and its highest was HK$7.11 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is €33.99B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 29 days.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
China Resources Pharmaceutical Group Ltd. released its earnings results on Mar 26, 2025. The company reported HK$0.123 earnings per share for the quarter, missing the consensus estimate of HK$0.235 by -HK$0.113.
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Overvalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. pays a Notavailable dividend of HK$0.056 which represents an annual dividend yield of 4.77%. See more information on China Resources Pharmaceutical Group Ltd. dividends here
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate is 0.42.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
China Resources Pharmaceutical Group Ltd. reported an EPS of HK$0.123 in its last earnings report, missing expectations of HK$0.235. Following the earnings report the stock price went down -4.944%.
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:3320
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.22%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. (3320) is a leading integrated pharmaceutical company in China, engaged in the manufacturing, distribution, and retail of pharmaceutical and healthcare products. The company operates across various sectors including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. Its core products and services encompass a wide range of therapeutic areas, providing comprehensive healthcare solutions to meet diverse consumer needs.
Technical Analysis
Sino Biopharmaceutical
―
Livzon Pharmaceutical Group
―
Shanghai Pharmaceuticals Holding Co
―
CSPC Pharmaceutical Group
―
Pacific Basin Shipping
―